Amarin Corp Plc (AMRN)

[ggwpq]

If FDA decides to wait for the outcome study before approving V for ANCHOR, it will send the wrong message to the medical community. Lovaza would continue to be prescribed off-label, causing more AFIB and increased LDL for at-risk patients. Why would FDA want that to happen? Unless it's totally corrupt and in bed with BP like GSK.